Issue Highlights.

Tofacitinib is an oral, small-molecule Janus Kinase inhibitor approved by the FDA for the treatment of moderate to severe ulcerative colitis (UC) in adult patients.1 Tofacitinib was associated with higher overall infection rates compared to placebo,2 and higher rates of reactivation of herpes zoster. Furthermore, in a safety trial with rheumatoid arthritis patients, there was a high rate of pulmonary embolism and all-cause mortality with tofacitinib 10 mg twice daily, as compared to patients treated with TNFα antagonists.